Abstract. Zinc finger protein X-linked (ZFX) is a zinc finger transcription factor and plays a significant role in the self-renewal ability of embryonic stem cells and various cancers. However, its expression and function in colorectal cancer (CRC) remain unclear. In the present study, we evaluated the expression of ZFX in CRC using quantitative polymerase chain reaction (qPCR), western blot analysis and immunohistochemistry (IHC), and further explored its potential functions in CRC cell lines using cell counting kit-8 and Transwell invasion assays. qPCR and western blot analysis revealed that ZFX was significantly upregulated in CRC tissues; IHC further confirmed this finding, revealing that higher expression of ZFX was significantly associated with larger tumor size (P=0.01), higher pathological stage (P=0.02), depth of invasion (P= 0.047), lymph node invasion (P= 0.02) and higher American Joint Committee on Cancer (AJCC) stage (P= 0.04). CRC patients with higher ZFX expression also exhibited significantly shorter survival times (P= 0.019). Moreover, knockdown of ZFX significantly suppressed proliferation and invasion in CRC cell lines HCT116 and LoVo. These results suggest that ZFX plays a notable role in CRC tumorigenicity and may serve as a novel marker and therapeutic target for CRC.
Introduction
Colorectal cancer (CRC) is the third most common type of cancer worldwide, with over 1.4 million new cancer cases and 50,000 mortalities reported in 2013 (1) . However, the biological and molecular mechanisms underlying CRC development remain largely unknown.
Zinc finger protein X-linked (ZFX), a zinc finger protein of the Zfy family, is a transcriptional factor encoded on the mammalian X chromosome which is highly conserved in vertebrates. The full-length ZFX protein contains a DNA-binding domain, an acidic transcriptional activation domain and a nuclear localization sequence (2) . Previous studies have demonstrated elevated levels of ZFX in pluripotent embryonic and hematopoietic stem cells, which is required for self-renewal ability (3, 4) . Overexpression of ZFX has also been demonstrated to confer self-renewal capability in hepatocellular carcinoma (5) . In addition, previous studies have revealed that ZFX plays a notable role in regulating the transcription of genes necessary for cell proliferation, cell cycle and cell death (6, 7) . Therefore, it is speculated that ZFX may also be active in cancers and may represent anti-cancer targets. Notably, ZFX is associated with a number of human cancers, including glioblastoma (8, 9) , breast cancer (10), osteosarcoma (11, 12) , lung cancer (13, 14) , gallbladder cancer (15), prostate cancer (16), laryngeal squamous cell carcinoma (17) and gastric cancer (18) . Amini et al also identified that ZFX was significantly upregulated in colon cancer tissues and cell lines (19) . However, the biological function of ZFX in CRC remains unclear.
In this study, we firstly detected the expression pattern of ZFX in CRC and revealed that the upregulation of ZFX is strongly associated with advanced tumor stage and shorter survival in CRC patients. Next, we explored the potential functions of ZFX in CRC by depletion of ZFX using small interfering RNA (siRNA) and observed that knockdown of ZFX significantly suppressed CRC cell growth and invasion. Using these approaches we aim to elucidate the role of ZFX in the development of CRC and evaluate ZFX as a potential biomarker for the prognosis of CRC.
Materials and methods
Human CRC specimens. A total of 30 CRC specimens were obtained for use in this study from the First Hospital of Jiaxing, China, between January 2013 and May 2014. The study was approved by the ethics committee of the same hospital, and written informed consent was obtained from all participants in accordance with the provisions of the Helsinki Declaration of 1975. One tissue microarray including 90 pairs of CRC and corresponding normal tissues was purchased from BioChip (Shanghai, China).
Primary antibodies. Anti-ZFX antibody was purchased from Sigma-Aldrich (St. Louis, MO, USA) for immunohistochemical analysis and western blot analysis, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Quantitative polymerase chain reaction (qPCR). Total RNA was extracted from 30 pairs of matched CRC tissues using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA). All tissues were examined histologically and all matched non-tumor tissues were confirmed to be normal. First-strand cDNA was synthesized using the PrimeScript™ RT reagent kit (Takara, Shiga, Japan) according to the manufacturer's instructions. qPCR was performed using an ABI Prism 7900HT sequence detection system (Applied Biosystems Life Technologies, Foster City, CA, USA) with SYBR ® Premix Ex Taq™ II (Takara). 18s RNA was used as an internal control. The primer sequences were as follows: ZFX, 5'-GGCAGTCCACAGCAAGAAC-3' (forward) and 5'-TTGG-TAT C C GAGA A AGT CAGA AG -3' (r eve r s e); 18s, 5'-CGGACAGGATTGACAGATTGATAGC-3' (forward) and 5'-TGCCAGAGTCTCGTTCGTTATCG-3' (reverse).
Western blot analysis. Total proteins were harvested from tissues or cells, and standard western blot analysis was performed using anti-ZFX and anti-GAPDH antibodies. All primary antibodies were used at a 1:1000 dilution. Peroxidase-conjugated anti-rabbit IgG secondary antibody was purchased from Kangchen Biotechnology (Shanghai, China) and used at a 1:5000 dilution.
Immunohistochemistry (IHC).
IHC was conducted using a standard streptavidin-biotin-peroxidase complex method. Briefly, paraffin-embedded slices were deparaffinized and rehydrated. Endogenous peroxidase was blocked with 0.3% H 2 O 2 for 15 min at room temperature, then the slides were microwaved for antigen retrieval. Following antigen retrieval, the sections were blocked with sheep serum for 30 min at room temperature and then treated with rabbit anti-ZFX (1:300) at 4˚C overnight. Samples incubated with phosphate-buffered saline (PBS) were used as negative controls. Immunolabeling was detected using a diaminobenzidine detection kit (Maixin biotechnology, Fuzhou, China).
Cell culture. Human CRC cell lines HCT116 and LoVo were maintained in RPMI-1640 medium (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum and cultured in a humidified incubator at 37˚C under 5% CO 2 .
RNA interference. All siRNAs specifically targeting ZFX were synthesized by GenePharma (Shanghai, China) using the following sequence: 5'-GACGGGUGAUUCUAUACAUTT-3' , 5'-GUCGGAAAUUGAUCCUUGUTT-3' and 5'-GCAACA GAGUGAGCUUAAATT-3'. The three siRNAs were used as a pool for siRNA transfection. Non-specific siRNAs (GenePharma) were used as a negative control.
Cell proliferation assay. HCT116 or LoVo Cells were seeded in 96-well plates at 5,000 cells/well following transfection. Cell proliferation was evaluated after 24, 48 and 72 h using cell counting kit-8 (Dojindo, Tokyo, Japan) according to the manufacturer's instructions.
Transwell invasion assay. Transwell cell invasion assays were performed using Boyden chambers with filter inserts (pore size, 8 µm) coated with 40 µg Matrigel in 24-well plates. Twenty-four hours after transfection with or without siRNA, cells were harvested, and 100 µl serum-free media containing 2x10 5 cells was added into the upper chamber, while 600 µl medium with 20% fetal bovine serum was placed in the lower chamber. Following incubation for 24 h, the cells were fixed in 4% formaldehyde and stained with 0.1% crystal violet in PBS for 30 min at room temperature. Cells on the lower side of the filters were counted under light microscopy in ten randomly selected fields of each filter.
Statistical analysis. Data from at least three independent experiments are presented as the means ± standard deviation. Differences between two groups were compared using Student's paired t-test. The expression of ZFX in CRC tissues was analyzed using the χ 2 test. P<0.05 was considered to indicate a statistically significant difference.
Results

ZFX is highly expressed in CRC tissues.
First, the ZFX expression level was investigated in normal colorectal tissues and CRC tissues by qPCR and western blot analysis. The results suggested that ZFX mRNA was highly expressed in 66.7% of CRC tissues (P=0.0005, Fig. 1A and B) . Western blot analysis of 20 paired CRC tissues further confirmed this finding ( Fig. 1C and D) .
Next, ZFX expression in 90 paired CRC tissues was analyzed by IHC, which revealed that ZFX was significantly upregulated in CRC tissues compared with the corresponding non-tumor tissues (P<0.001, Fig. 2A and B) . As shown in Fig. 2 , ZFX was readily detected in the plasma and part of the nuclei of CRC tissues, whereas little or no staining was observed in the normal colorectal tissues.
ZFX expression is correlated with severity of CRC. To test whether ZFX expression was correlated with various clinicopathological features of CRC, 90 CRC cases were stratified by ZFX expression as determined by IHC. ZFX upregulation was observed to be significantly associated with larger tumor size (P= 0.01), higher pathological stage (P= 0.02), depth of invasion (P=0.047), lymph node invasion (P=0.02) and higher American Joint Committee on Cancer (AJCC) stage (P=0.04), as detailed in Table I .
Given that ZFX is highly expressed in CRC tissues and is associated with various clinicopathological features of CRC, we further tested whether ZFX expression was correlated with poor prognosis in CRC patients. As shown in Fig. 3 , CRC patients with higher ZFX expression exhibited a significantly shorter survival time (P= 0.019). These results strongly suggest that ZFX expression is correlated with poor prognosis in CRC.
Knockdown of ZFX suppresses CRC cell proliferation and invasion. As ZFX was significantly upregulated in CRC tissues and associated with the severity of CRC, we next explored its potential function in CRC cells. To test this, specific siRNAs were employed to knock down ZFX expression in the human CRC cell lines HCT116 and LoVo. qPCR and western blot analysis revealed efficient knockdown of ZFX in HCT116 and LoVo cell lines (Fig. 4C and D) . The cell counting kit-8 assay was adopted to explore the influence of proliferation by depletion of ZFX and revealed that suppression of ZFX significantly decreased the proliferation rate of HCT116 and LoVo cell lines ( Fig. 4A and B) . Transwell assay was used to further study the association of ZFX with cell invasion. Knockdown of ZFX significantly decreased the number of penetrated HCT116 and LoVo cells, which suggested a substantial loss of cell invasion ability by depletion of ZFX (Fig. 5A and B) .
Discussion
It was reported that zinc finger-containing transcription factors are involved in various physiological functions including differentiation, migration and proliferation, thus contributing to cancer development (20) . As ZNF proteins contain an acidic transcriptional activation domain, ZFX may function as a transcription factor which promotes the transcription of growth factors or oncogenes (21) . In fact, a number of previous studies have suggested ZFX as a transcriptional regulator and oncogene in various cancer types. As examples, a study by Wu et By investigating the expression pattern and function of ZFX in the context of CRC, the present study provides evidence that ZFX may function as an oncogene in CRC progression. ZFX was demonstrated to be upregulated in CRC and was associated with tumor size, pathological stage, lymph node invasion, depth of invasion and AJCC stage. More significantly, it was noted that CRC patients with higher ZFX expression levels exhibited a significantly shorter survival time. These clinicopathological findings suggest that ZFX may contribute to the malignant phenotypes of CRC. In cultured CRC cell lines, knockdown of ZFX inhibited CRC cell proliferation and invasion. These results were consistent with previous studies in breast, gastric and lung cancers (10, 13, 18) . The strong correlation between ZFX and CRC tumor size, invasion and AJCC stage highlights the potential value of ZFX as a novel biomarker for CRC.
Previous studies have identified that ZFX regulates the expression and signaling pathway function of various genes, including ERK-MAPK, ERK2, MMP-2, CyclinD1, Stat3, Akt and c-myc. In fact, in these genes, signaling pathways along with certain other pathways, including wnt/β-catenin, play essential roles in CRC progression (22) (23) (24) (25) (26) . The correlation between ZFX and these genes and pathways in CRC progression requires further study.
In summary, our study confirmed that ZFX was overexpressed in CRC, and was associated with tumor size, lymph node invasion, depth of invasion and overall survival time. Knockdown of ZFX in CRC cell lines inhibited cell proliferation and invasion. These results highlight the potential role of ZFX as a novel biomarker as well as a sensitive therapeutic target for CRC.
